Ligand Pharmaceuticals Inc
General ticker "LGND" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $2.2B
Ligand Pharmaceuticals Inc follows the US Stock Market performance with the rate: 65.1%.
Estimated limits based on current volatility of 2.6%: low 112.42$, high 118.47$
Factors to consider:
- Current price 60.2% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [43.30$, 71.03$]
- 2024-12-30 to 2025-12-30 estimated range: [46.49$, 74.39$]
Financial Metrics affecting the LGND estimates:
- Positive: Non-GAAP EPS, $ of 5.77 > 2.29
- Positive: 1.03 < Operating profit margin, % of 8.95
- Negative: Inventory ratio change, % of 9.04 > 1.08
- Positive: Interest expense per share, $ of 0.04 <= 0.14
- Positive: -0.96 < Investing cash flow per share, $ of -0.68
- Positive: 2.86 < Return on assets ratio (scaled to [-100,100]) of 6.21
- Negative: Industry operating cash flow per share per price (median), % of -12.63 <= 3.85
Short-term LGND quotes
Long-term LGND plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $279.14MM | $196.25MM | $133.44MM |
| Operating Expenses | $175.29MM | $193.21MM | $121.49MM |
| Operating Income | $103.85MM | $3.04MM | $11.94MM |
| Non-Operating Income | $-31.65MM | $32.97MM | $51.72MM |
| Interest Expense | $18.74MM | $1.80MM | $0.66MM |
| R&D Expense | $69.01MM | $36.08MM | $24.54MM |
| Income(Loss) | $72.20MM | $36.01MM | $63.66MM |
| Taxes | $-4.15MM | $41.23MM | $9.84MM |
| Other Income(Loss) | $-19.21MM | $-28.14MM | $-1.67MM |
| Profit(Loss) | $57.14MM | $-33.36MM | $52.15MM |
| Stockholders Equity | $821.16MM | $597.49MM | $700.91MM |
| Inventory | $27.33MM | $13.29MM | $23.97MM |
| Assets | $1,297.59MM | $762.67MM | $787.22MM |
| Operating Cash Flow | $78.80MM | $137.85MM | $49.58MM |
| Capital expenditure | $8.76MM | $17.92MM | $3.52MM |
| Investing Cash Flow | $30.52MM | $163.62MM | $-11.68MM |
| Financing Cash Flow | $-137.76MM | $-275.99MM | $-59.95MM |
| Earnings Per Share* | $3.44 | $-0.31 | $3.02 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.